PRESS RELEASE published on 11/15/2023 at 12:45, 11 months 23 days ago NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
PRESS RELEASE published on 11/14/2023 at 12:45, 11 months 24 days ago Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE published on 10/16/2023 at 12:45, 1 year ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE published on 10/12/2023 at 12:45, 1 year ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 1 year 2 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 1 year 3 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 1 year 4 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 1 year 4 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
PRESS RELEASE published on 05/31/2023 at 12:40, 1 year 5 months ago NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
PRESS RELEASE published on 05/16/2023 at 12:45, 1 year 5 months ago NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
Published on 11/08/2024 at 16:00, 1 hour 42 minutes ago MANAMAURI, the High-Quality Energy Drink Brand, Joins EastBridge Global Investments for Major International Expansion
Published on 11/08/2024 at 15:00, 2 hours 42 minutes ago Hoverfly Technologies Promotes Steve Topping to Chief Operating Officer
Published on 11/08/2024 at 15:00, 2 hours 42 minutes ago The Biltmore Los Angeles Welcomes Matthias Kaiser as New General Manager
Published on 11/08/2024 at 15:00, 2 hours 42 minutes ago SustainableIT.org Joins COP29 To Champion Climate Solutions and Responsible AI in Baku, Azerbaijan
Published on 11/08/2024 at 16:15, 1 hour 27 minutes ago CGTN: China vows continued efforts to build Asia-Pacific community with shared future
Published on 11/08/2024 at 15:46, 1 hour 56 minutes ago Original-Research: Koenig & Bauer AG (von Montega AG): Kaufen (zuvor: Halten)
Published on 11/08/2024 at 15:13, 2 hours 29 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/08/2024 at 17:35, 7 minutes ago Déclaration du nombre d'actions composant le capital et du nombre total de droits de vote au 31 octobre 2024
Published on 11/08/2024 at 17:35, 7 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2024
Published on 11/08/2024 at 12:32, 5 hours 10 minutes ago Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
Published on 11/08/2024 at 12:32, 5 hours 10 minutes ago Louis Hachette Group annonce la publication de son Document d’Information en vue de sa cotation sur Euronext Growth (Paris)
Published on 11/08/2024 at 12:15, 5 hours 27 minutes ago Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
